FSCS Fact Sheet: First Trust SMID Capital Strength ETF
Share
$37.11
close, Nov 18, 2026
Over the year to Nov 18, 2026, FSCS returned +7.8% in total and charged 0.60% a year.
- 1-year total return
- +7.8%
- to Nov 18, 2026
- Expense ratio
- 0.60%
- a year
- Net assets
- $61m
- on Nov 17, 2026
- Net flow, last 5 trading days
- $0
- daily basis to Nov 17, 2026
Growth of $10,000, 1 year
FSCS $10,782 +7.8% · IWV $11,199 +12.0% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month+1.9%
3 months−2.2%
Year to date+4.8%
1 year+7.8%
3 years+36.0%
5 years+31.0%
Total return, distributions reinvested, each window to Nov 18, 2026.
Ten largest positions
HoldingWeight
Neurocrine Biosciences, Inc.1.20%
Hasbro, Inc.1.19%
Allegion Public Limited Company1.18%
Veralto Corporation1.16%
Healthcare Services Group, Inc.1.15%
Interparfums, Inc.1.13%
Jazz Pharmaceuticals Plc1.13%
ACI Worldwide, Inc.1.12%
Assurant, Inc.1.12%
Corpay, Inc.1.12%
FSCS top ten by weight, 11.5% of the fund, of its 100 equity positions, from the holdings published by its issuer for Nov 17, 2026.
Facts
Equity fund · Tracks the SMID Capital Strength Index · First traded Jun 22, 2017 · Benchmark Its own holdings, as of Nov 17, 2026